FY2017 EPS Estimates for Lipocine Inc. Decreased by Analyst (LPCN)
Lipocine Inc. (NASDAQ:LPCN) – Stock analysts at Roth Capital dropped their FY2017 earnings per share (EPS) estimates for Lipocine in a research report issued on Monday. Roth Capital analyst M. Higgins now expects that the firm will post earnings of ($1.54) per share for the year, down from their previous estimate of ($1.47).
Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05.
A number of other research firms have also commented on LPCN. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price objective (down previously from $15.00) on shares of Lipocine in a research note on Saturday, July 2nd. HC Wainwright initiated coverage on shares of Lipocine in a research report on Monday. They issued a “buy” rating and a $25.00 target price for the company.
Lipocine (NASDAQ:LPCN) traded up 0.56% during trading on Wednesday, reaching $3.62. 298,219 shares of the company’s stock were exchanged. The company’s 50-day moving average is $3.95 and its 200-day moving average is $6.18. Lipocine has a 1-year low of $2.51 and a 1-year high of $14.80. The company’s market capitalization is $66.09 million.
A number of large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new stake in Lipocine during the second quarter worth about $106,000. BlackRock Investment Management LLC increased its stake in Lipocine by 2,370.7% in the second quarter. BlackRock Investment Management LLC now owns 62,707 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 60,169 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in Lipocine during the first quarter worth about $385,000. DRW Securities LLC bought a new stake in Lipocine during the second quarter worth about $443,000. Finally, State Street Corp increased its stake in Lipocine by 1,408.9% in the second quarter. State Street Corp now owns 200,679 shares of the specialty pharmaceutical company’s stock worth $609,000 after buying an additional 187,379 shares during the last quarter. Institutional investors own 47.22% of the company’s stock.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Stock Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related stocks with our FREE daily email newsletter.